四川大学学报（医学版）
四川大學學報（醫學版）
사천대학학보（의학판）
JOURNAL OF SICHUAN UNIVERSITY(MEDICAL SCIENCE EDITION)
2009年
6期
1066-1070
,共5页
李游%范平%白怀%万德花%刘宏伟
李遊%範平%白懷%萬德花%劉宏偉
리유%범평%백부%만덕화%류굉위
多囊卵巢综合征%血小板活化因子乙酰水解酶%血脂%胰岛素抵抗
多囊卵巢綜閤徵%血小闆活化因子乙酰水解酶%血脂%胰島素牴抗
다낭란소종합정%혈소판활화인자을선수해매%혈지%이도소저항
Polycystic ovary syndrome%Platelet activating factor-acetylhydrolase%Lipid profile Insulin resistance
目的 探讨多囊卵巢综合征(PCOS)患者血小板活化因子乙酰水解酶(PAF-AH)活性及其与糖脂代谢的关系.方法 按照鹿特丹标准筛选PCOS患者87例,同时选取年龄匹配的健康妇女83名作为对照.① 用化学发光法检测血清雌二醇(E2)、总睾酮(TT)、黄体生成素(LH)、促卵泡激素(FSH)、空腹胰岛素(FINS);② 用酶法试剂盒测定空腹血糖(FGLU)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C);③ 用[~3H-acelty] PAF示踪三氯醋酸沉淀法检测血浆PAF-AH活性.结果 ① PCOS组体重指数(BMI)、腰臀比(WHR)、F-G评分、血清TT水平、LH/FSH比值高于对照组(P<0.01).② PCOS组血清FINS、胰岛素抵抗指数(HOMA-IR)、TG、TC、LDL-C、非高密度脂蛋白胆固醇(non-HDL-C)和致动脉粥样硬化指数(AI)高于对照组(P<0.01),而HDL-C水平低于对照组(P<0.01).但血浆PAF-AH活性两组间差异无统计学意义(P>0.05).③ 非肥胖PCOS患者(BMI＜25 kg/m~2)FINS、HOMA-IR、LDL-C、non-HDL-C、AI高于非肥胖对照妇女(P<0.05).肥胖PCOS患者(BMI≥25 kg/m~2)除了更严重的上述代谢异常外,FGLU、TG、TC、BMI、WHR、收缩压(SBP)、舒张压(DBP)也明显升高(P<0.05),HDL-C水平明显降低(P<0.05).然而非肥胖对照、非肥胖PCOS与肥胖PCOS三亚组间血浆PAF-AH活性差异无统计学意义(P>0.05).④ Person相关分析表明:PCOS组血浆PAF-AH活性分别与non-HDL-C、LDL-C、AI、TG、TG、WHR呈正相关,与HDL-C呈负相关(P<0.05).多重线性回归表明:non-HDL-C与SBP是PCOS组血浆PAF-AH活性有意义的预测因子(P<0.05).结论 PCOS组血浆PAF-AH活性与对照组比较无明显改变,血脂特别是胆固醇与血浆PAF-AH活性相关联.肥胖PCOS患者比非肥胖PCOS患者表现出更严重的脂代谢异常与胰岛素抵抗.
目的 探討多囊卵巢綜閤徵(PCOS)患者血小闆活化因子乙酰水解酶(PAF-AH)活性及其與糖脂代謝的關繫.方法 按照鹿特丹標準篩選PCOS患者87例,同時選取年齡匹配的健康婦女83名作為對照.① 用化學髮光法檢測血清雌二醇(E2)、總睪酮(TT)、黃體生成素(LH)、促卵泡激素(FSH)、空腹胰島素(FINS);② 用酶法試劑盒測定空腹血糖(FGLU)、總膽固醇(TC)、甘油三酯(TG)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C);③ 用[~3H-acelty] PAF示蹤三氯醋痠沉澱法檢測血漿PAF-AH活性.結果 ① PCOS組體重指數(BMI)、腰臀比(WHR)、F-G評分、血清TT水平、LH/FSH比值高于對照組(P<0.01).② PCOS組血清FINS、胰島素牴抗指數(HOMA-IR)、TG、TC、LDL-C、非高密度脂蛋白膽固醇(non-HDL-C)和緻動脈粥樣硬化指數(AI)高于對照組(P<0.01),而HDL-C水平低于對照組(P<0.01).但血漿PAF-AH活性兩組間差異無統計學意義(P>0.05).③ 非肥胖PCOS患者(BMI＜25 kg/m~2)FINS、HOMA-IR、LDL-C、non-HDL-C、AI高于非肥胖對照婦女(P<0.05).肥胖PCOS患者(BMI≥25 kg/m~2)除瞭更嚴重的上述代謝異常外,FGLU、TG、TC、BMI、WHR、收縮壓(SBP)、舒張壓(DBP)也明顯升高(P<0.05),HDL-C水平明顯降低(P<0.05).然而非肥胖對照、非肥胖PCOS與肥胖PCOS三亞組間血漿PAF-AH活性差異無統計學意義(P>0.05).④ Person相關分析錶明:PCOS組血漿PAF-AH活性分彆與non-HDL-C、LDL-C、AI、TG、TG、WHR呈正相關,與HDL-C呈負相關(P<0.05).多重線性迴歸錶明:non-HDL-C與SBP是PCOS組血漿PAF-AH活性有意義的預測因子(P<0.05).結論 PCOS組血漿PAF-AH活性與對照組比較無明顯改變,血脂特彆是膽固醇與血漿PAF-AH活性相關聯.肥胖PCOS患者比非肥胖PCOS患者錶現齣更嚴重的脂代謝異常與胰島素牴抗.
목적 탐토다낭란소종합정(PCOS)환자혈소판활화인자을선수해매(PAF-AH)활성급기여당지대사적관계.방법 안조록특단표준사선PCOS환자87례,동시선취년령필배적건강부녀83명작위대조.① 용화학발광법검측혈청자이순(E2)、총고동(TT)、황체생성소(LH)、촉란포격소(FSH)、공복이도소(FINS);② 용매법시제합측정공복혈당(FGLU)、총담고순(TC)、감유삼지(TG)、고밀도지단백담고순(HDL-C)、저밀도지단백담고순(LDL-C);③ 용[~3H-acelty] PAF시종삼록작산침정법검측혈장PAF-AH활성.결과 ① PCOS조체중지수(BMI)、요둔비(WHR)、F-G평분、혈청TT수평、LH/FSH비치고우대조조(P<0.01).② PCOS조혈청FINS、이도소저항지수(HOMA-IR)、TG、TC、LDL-C、비고밀도지단백담고순(non-HDL-C)화치동맥죽양경화지수(AI)고우대조조(P<0.01),이HDL-C수평저우대조조(P<0.01).단혈장PAF-AH활성량조간차이무통계학의의(P>0.05).③ 비비반PCOS환자(BMI＜25 kg/m~2)FINS、HOMA-IR、LDL-C、non-HDL-C、AI고우비비반대조부녀(P<0.05).비반PCOS환자(BMI≥25 kg/m~2)제료경엄중적상술대사이상외,FGLU、TG、TC、BMI、WHR、수축압(SBP)、서장압(DBP)야명현승고(P<0.05),HDL-C수평명현강저(P<0.05).연이비비반대조、비비반PCOS여비반PCOS삼아조간혈장PAF-AH활성차이무통계학의의(P>0.05).④ Person상관분석표명:PCOS조혈장PAF-AH활성분별여non-HDL-C、LDL-C、AI、TG、TG、WHR정정상관,여HDL-C정부상관(P<0.05).다중선성회귀표명:non-HDL-C여SBP시PCOS조혈장PAF-AH활성유의의적예측인자(P<0.05).결론 PCOS조혈장PAF-AH활성여대조조비교무명현개변,혈지특별시담고순여혈장PAF-AH활성상관련.비반PCOS환자비비비반PCOS환자표현출경엄중적지대사이상여이도소저항.
Objective To investigate the association between plasma platelet activating factor (PAF)-acetylhydrolase (PAF-AH) activity and polycystic ovary syndrome(PCOS). Methods A total of 87 patients with PCOS were recruited in this study. Eighty three age-matched women with healthy ovulation served as controls. Plasma PAF-AH activity was measured by the trichloroacetic acid precipitation procedure using [3 H-acetyl] PAF as a substrate. Fasting insulin (FINS), estradiol (E2),total testosterone (TT), luteinizing hormone (LH), and follicle stimulating hormone (FSH) were determined by chemiluminescent method. The metabolic profile was investigated by measuring FINS, fasting glucose (FGLU) . total cholesterol (TO , triglycerides (TG) , high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C). Results The patients with PCOS had higher BMI, WHR, F-G score, serum TT and LH/FSH radio than the controls (P<0. 05). The patients with PCSO had higher serum FINS, HOMA-IR, TG, TC, LDL-C, non-HDL-C and atherogenic index (AD, and lower HDL-C level than the controls (P<0. 05). No significant difference in plasma PAF-AH activity was found between the patients with PCOS and the controls (P>0.05). A progressive increase in FINS, HOMA-IR, TC, LDL-C, non-HDL-C and AI, and decrease in HDL-C level were found from non-obese healthy women (BMK25 kg/m~2) to non-obese patients, and to obese patients (BMI≥25 kg/m~2) with PCOS (P<0. 05). In addition, the obese patients with PCOS had higher BMI, WHR, SBP, DBP than the controls and the non-obese patients with PCOS. But no significant difference in plasma PAF-AH activity was found between the three groups of women (P>0. 05). The plasma PAF-AH activity was positively correlated with AI, non-HDL-C, LDL-C, TC, TG, and WHR, and negatively correlated with HDL-C level (P<0. 05). Non-HDL-C and SBP were predictors for plasma PAF-AH activity in patients with PCOS. Conclusions Patients with PCOS have similar total plasma PAF-AH activity as healthy women. Patients with PCOS present more atherogenic metabolic profilet especially in those with obesity.
